BioRestorative Therapies' combined Management Team, Board of Directors and Scientific Advisory Board members have extensive experience in the healthcare industry. Together we have expert experience in the stem cell science, medical-related services, life science services marketing, public company business management and financing, IP development and licensing, business acquisitions, and strategic partnering.


Mark R. Weinreb, M.S. - Chief Executive Officer, President, and Chairman

Mark Weinreb is an early pioneer in the field of regenerative medicine and cellular therapy and has significant experience in running public companies. He has served as our Chief Executive Officer since October 2010, as our President since February 2012, and as our Chairman of the Board since April 2011.

From February 2003 to January 2006 he served as the Chief Executive Officer and Chairman of the Board of Directors of Phase III Medical, Inc. where he orchestrated the acquisition of NS California, an adult stem cell collection company that became NeoStem, Inc. (NASDAQ: NBS), a public international biopharmaceutical company engaged in, among other things, adult stem cell-related science. From June 2006 through October 2009, Mr. Weinreb served as President and a director of NeoStem.

In 1976, Mr. Weinreb joined Bio Health Laboratories, Inc., a state-of-the-art medical diagnostic laboratory providing clinical testing services for physicians, hospitals, and other medical laboratories. He became the laboratory administrator in 1978 and then an owner and the laboratory’s Chief Operating Officer in 1982. In such capacity, he oversaw all technical and business facets, including finance and laboratory science technology.

In 1992, Mr. Weinreb founded Big City Bagels, Inc., a national chain of franchised upscale bagel bakeries and became its Chairman and Chief Executive Officer. Big City Bagels went public in 1995, and in 1999 Mr. Weinreb redirected the company and completed a merger with an Internet service provider.

From 2000 to 2002, Mr. Weinreb served as Chief Executive Officer of Jestertek, Inc., a software development company pioneering gesture recognition and control using advanced interactive proprietary video technology.

Mr. Weinreb received a Bachelor of Arts degree in 1975 from Northwestern University and a Master of Science degree in 1982 in Medical Biology from C.W. Post, Long Island University.

Mandy D. Clyde - Vice President of Operations and Corporate Secretary

Mandy Clyde has been our Vice President of Operations since August 2009. She has served as our Corporate Secretary since December 2010 and served on our Board from September 2010 to April 2011.

From 2006 to 2009, Mrs. Clyde held positions within PRIME Education, LLC, an accredited provider of medical and professional education. She oversaw live medical education programs throughout the U.S. for major pharmaceutical sponsors including Novartis, Pfizer and Sanofi. Mrs. Clyde spearheaded company programs on Needs Assessment, Outcomes Analysis/Reporting and Transformational Learning. Mrs. Clyde has experience in content editing for medical educational programs and has been a contributing author on topics including Alzheimer’s disease, breast cancer, sleep apnea and adult learning.

From 2005 to 2006, Mrs. Clyde served as surgical coordinator for Eye Surgery Associates and the Rand Eye Institute, two prominent ophthalmology practices in Florida. Prior to this, between 2003 and 2005, she was an optometric technician for optometry practices including LensCrafters. She received a degree in Biology with a pre-medicine concentration from Mercyhurst University.

Francisco Silva - Vice President of Research and Development and Chief Scientist

Francisco Silva joined BRT in April 2011. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs.

From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences LLC, companies engaged in the commercialization of human-based biologics for both research and therapeutic applications.

From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms.

Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research.

Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.

Robert Paccasassi - Vice President, Quality and Compliance

Robert Paccasassi joined BioRestorative Therapies in September 2015 and holds the title of Vice President, Quality and Compliance. Mr. Paccasassi has over 20 years of experience in highly regulated product operations, with specific expertise in GMP (large and small molecule) clinical and commercial quality assurance and regulatory compliance leadership roles.

Prior to joining Biorestorative Therapies, Mr. Paccasassi was the Corporate Director of Quality Systems (GMP) at Merck KGaA (Darmstadt, Germany), the oldest pharmaceutical and chemical company in the world with over 50,000 employees and operations in 66 countries worldwide. Within this role, Mr. Paccasassi was responsible for leading the ongoing development and implementation of the Corporate Quality Unit’s global GMP policies, processes, directives and operational improvement initiatives.

Prior to his role at Merck KGaA, Mr. Paccasassi held key quality and compliance management roles at EMD Serono, Biogen Idec, Millennium Pharmaceuticals and Regeneron Pharmaceuticals. He previously managed site build-out and operations in Rhode Island and Massachusetts for biotechnology firm, Curative Health Services, and began his career as a Clinical Laboratory Scientist in the field of Immunohematology at Brigham & Woman’s Hospital (Boston, MA). Mr. Paccasassi holds a Master’s degree in Business Administration (MBA) from Johnson & Wales University and a Bachelor of Science degree in Clinical Laboratory Science / Biology from the University of Rhode Island.

Adam Bergstein - Senior Vice President, Planning and Business Development

Mr. Bergstein joined BioResorative Therapies as its Senior Vice President, Planning and Business Development in January of 2018.

From 2008 until 2017, Mr. Bergstein founded and operated PharmaShield, an analytics company that created the first known data model that accurately predicts litigation loss and the timing of outcomes in branded pharmaceutical patent cases. From 2006 through 2008, Mr. Bergstein worked as a consultant to a health economics group inside RAND Corporation, during which time he created derivatives to help mitigate risk within the broader healthcare markets. From 1998 through 2006, Mr. Bergstein was a private equity investor in the healthcare and technology sectors.

Mr. Bergstein has an MBA from the J.L. Kellogg Graduate School of Management with concentrations in finance and organizational behavior, as well as a Bachelor of Arts degree in Economics with distinction from the University of Pennsylvania.

BioRestorative Therapies: A Stem Cell Biotechnology Company